+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuropathic Pain Drug Market by Type, Treatment, Indication, Distribution, End User - Global Forecast 2025-2030- Product Image
Neuropathic Pain Drug Market by Type, Treatment, Indication, Distribution, End User - Global Forecast 2025-2030- Product Image
Sale

Neuropathic Pain Drug Market by Type, Treatment, Indication, Distribution, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968619
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neuropathic Pain Drug Market grew from USD 11.85 billion in 2023 to USD 12.90 billion in 2024. It is expected to continue growing at a CAGR of 9.93%, reaching USD 23.01 billion by 2030.

Neuropathic pain drugs are essential in addressing chronic pain conditions often arising from nerve damage due to diseases such as diabetes, shingles, spinal cord injuries, and multiple sclerosis. The necessity for these drugs is driven by the increasing prevalence of such conditions, alongside a growing aging population more susceptible to nerve-related ailments. Additionally, heightened awareness and diagnosis rates have further fueled demand. Applications for neuropathic pain drugs extend across treatments for peripheral neuropathy, postherpetic neuralgia, and trigeminal neuralgia, among others. The end-use scope involves hospitals, clinics, and research institutes, with a significant market presence in North America and Europe due to advanced healthcare infrastructures and favorable reimbursement policies.

Market growth is influenced by factors such as advancements in drug delivery systems, increasing investments in pharmaceutical R&D, and a growing emphasis on personalized medicine. The latest opportunities lie in the development of non-opioid therapeutics, which cater to a rising preference for alternatives owing to the opioid crisis. The expansion of telemedicine and e-health platforms also presents a promising avenue, enhancing access to medication and treatment adherence. However, challenges include stringent regulatory requirements and high costs associated with drug development and approval. The competitive landscape, dominated by a few key players, presents barriers to new entrants, while side effects and varied patient responses to existing drugs limit market growth further.

Innovation and research prospects are ripe for exploring advanced formulations and novel mechanisms of action, such as targeting specific pain pathways or utilizing biotechnology like gene therapy. Additionally, enhancing drug efficacy and safety profiles remains a focal point. To succeed, companies should invest in collaborations for drug discovery and development, emphasize patient-centric solutions, and actively engage with regulatory bodies to streamline approval processes. The market, while competitive, offers substantive growth opportunities for entities focused on innovation, cost-effective solutions, and strategic positioning to navigate its complexities effectively.

Understanding Market Dynamics in the Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalence of neurological disorders and diabetic neuropathy worldwide
    • Significant preference for personalized medicines for neuropathic treatment
    • Increase in the geriatric population raises the demand for neuropathic pain management
  • Market Restraints
    • Product recall and high cost of new drug development
  • Market Opportunities
    • Ongoing clinical trial for neuropathic pain treatment
    • Rising number of specialty neuropathy and pain centers and efforts to boost distribution
  • Market Challenges
    • Side effects associated with neuropathic pain drug

Exploring Porter’s Five Forces for the Neuropathic Pain Drug Market

Porter’s Five Forces framework further strengthens the insights of the Neuropathic Pain Drug Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Neuropathic Pain Drug Market

External macro-environmental factors deeply influence the performance of the Neuropathic Pain Drug Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathic Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Aptinyx Inc., Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Axsome Therapeutics, Inc., Bausch Health Companies Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, CARA THERAPEUTICS, INC., Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline PLC, Grünenthal Group, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Trevena Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Neuropathic Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Phantom Limb Pain
    • Post Herpetic Neuralgia
    • Post-traumatic Neuropathy
    • Trigeminal Neuralgia
  • Treatment
    • Antidepressant Drugs Type
      • Serotonin Noradrenaline
      • Tricyclic Antidepressants
    • Multimodal Therapy
    • NSAIDs Type
      • Ibuprofen
      • Naproxen
  • Indication
    • Diabetic Neuropathy
    • Spinal Stenosis
  • Distribution
    • Online Pharmacies
    • Retail Pharmacies & Drug Stores
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of neurological disorders and diabetic neuropathy worldwide
5.1.1.2. Significant preference for personalized medicines for neuropathic treatment
5.1.1.3. Increase in the geriatric population raises the demand for neuropathic pain management
5.1.2. Restraints
5.1.2.1. Product recall and high cost of new drug development
5.1.3. Opportunities
5.1.3.1. Ongoing clinical trial for neuropathic pain treatment
5.1.3.2. Rising number of specialty neuropathy and pain centers and efforts to boost distribution
5.1.4. Challenges
5.1.4.1. Side effects associated with neuropathic pain drug
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Neuropathic Pain Drug Market, by Type
6.1. Introduction
6.2. Phantom Limb Pain
6.3. Post Herpetic Neuralgia
6.4. Post-traumatic Neuropathy
6.5. Trigeminal Neuralgia
7. Neuropathic Pain Drug Market, by Treatment
7.1. Introduction
7.2. Antidepressant Drugs Type
7.2.1. Serotonin Noradrenaline
7.2.2. Tricyclic Antidepressants
7.3. Multimodal Therapy
7.4. NSAIDs Type
7.4.1. Ibuprofen
7.4.2. Naproxen
8. Neuropathic Pain Drug Market, by Indication
8.1. Introduction
8.2. Diabetic Neuropathy
8.3. Spinal Stenosis
9. Neuropathic Pain Drug Market, by Distribution
9.1. Introduction
9.2. Online Pharmacies
9.3. Retail Pharmacies & Drug Stores
10. Neuropathic Pain Drug Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
11. Americas Neuropathic Pain Drug Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Neuropathic Pain Drug Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Neuropathic Pain Drug Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Eli Lilly strikes USD 630 million deal with Confo Therapeutics for non-opioid neuropathic pain drug
14.3.2. Launch of AFD-NP Product For Neuropathic Pain Management
14.3.3. Akelos Receives NIH Grant To Continue Research On Nonopioid Alternative For Neuropathic Pain
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 2. NEUROPATHIC PAIN DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEUROPATHIC PAIN DRUG MARKET DYNAMICS
TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 59. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 93. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 94. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 96. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 100. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 103. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 114. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 115. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 117. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 154. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 156. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 157. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 159. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 181. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 185. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 186. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 188. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 191. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 192. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 199. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 202. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 205. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 206. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 207. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 209. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 218. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 220. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 221. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 223. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 247. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 248. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 249. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 251. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 253. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 255. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 256. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 258. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 281. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 282. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 283. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 286. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 302. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 304. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 305. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 307. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 316. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 318. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 323. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Neuropathic Pain Drug Market, which are profiled in this report, include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Aptinyx Inc.
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Axsome Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CARA THERAPEUTICS, INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Grünenthal Group
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 12.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 23.01 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Peripheral Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 260 Pages
  • Global
From
Neuropathic Pain Global Market Report 2024 - Product Image

Neuropathic Pain Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Neuropathic Pain - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Neuropathic Pain - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 110 Pages
  • Global
From
Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Neuropathic Pain - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 128 Pages
  • Global
From

About the Neuropathic Pain Drug Market

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline. Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.